Haemophilia specialist nurses’ perceptions of haemophilia B
14 paź 2021
O artykule
Kategoria artykułu: Clinical Practice
Data publikacji: 14 paź 2021
Zakres stron: 119 - 127
DOI: https://doi.org/10.2478/jhp-2021-0013
Słowa kluczowe
© 2021 Steve Chaplin et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Figure 1

Figure 2

Experience of use of factor IX products
Standard half-life | |||
Nonacog alfa | Benefix [ |
47 | 80% |
Nonacog gamma | Rixubis [ |
11 | 19% |
Extended half-life | |||
Albutrepenonacog alfa | Idelvion [ |
22 | 37% |
Eftrenonacog alfa | Alprolix [ |
36 | 61% |
Nonacog beta pegol | Refixia/Rebinyn [ |
13 | 22% |
Other | 17 | 29% |